Ruxolitinib

Generic Name
Ruxolitinib
Brand Names
Jakafi, Jakavi, Opzelura
Drug Type
Small Molecule
Chemical Formula
C17H18N6
CAS Number
941678-49-5
Unique Ingredient Identifier
82S8X8XX8H
Background

Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant act...

Indication

Ruxolitinib is indicated for the treatment of the following conditions:

Topical ruxolitinib is indicated for:

Associated Conditions
Acute Graft-Versus-Host Disease (GVHD), Chronic Graft-Versus-Host Disease, Non-segmental Vitiligo, Post Polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Myelofibrosis (PMF), High risk Myelofibrosis, Intermediate risk Myelofibrosis, Mild Atopic dermatitis, Moderate Atopic dermatitis, Refractory Polycythemia vera
Associated Therapies
-

Ruxolitinib in Patients With Myelofibrosis

Not yet recruiting
Conditions
First Posted Date
2023-03-10
Last Posted Date
2023-03-10
Lead Sponsor
Assiut University
Target Recruit Count
51
Registration Number
NCT05762874

Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2023-03-09
Last Posted Date
2024-01-09
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
20
Registration Number
NCT05762640

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

First Posted Date
2023-02-10
Last Posted Date
2023-02-10
Lead Sponsor
Incyte Corporation
Registration Number
NCT05722912

A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis

First Posted Date
2023-02-06
Last Posted Date
2024-08-14
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
18
Registration Number
NCT05714072
Locations
🇺🇸

Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States

and more 4 locations

Ruxolitinib as add-on Therapy in Steroid-refractory Graft-vs-host Disease

Phase 3
Completed
Conditions
Interventions
First Posted Date
2022-12-23
Last Posted Date
2024-03-05
Lead Sponsor
Yi-Lun Wang
Target Recruit Count
6
Registration Number
NCT05663827
Locations
🇨🇳

Chang Gung Memorial Hospital, Taoyuan, Taiwan

De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis

First Posted Date
2022-11-18
Last Posted Date
2024-10-01
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
56
Registration Number
NCT05622318
Locations
🇺🇸

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Phase 2
Completed
Conditions
Interventions
First Posted Date
2022-11-01
Last Posted Date
2024-12-06
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
115
Registration Number
NCT05600855
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-10-31
Last Posted Date
2024-11-06
Lead Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Target Recruit Count
40
Registration Number
NCT05599256
Locations
🇨🇳

Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China

Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2022-10-24
Last Posted Date
2024-10-29
Lead Sponsor
Jonathan Brammer
Target Recruit Count
28
Registration Number
NCT05592015
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath